Active surveillance with selective delayed intervention for favorable risk prostate cancer

Urologic Oncology: Seminars and Original Investigations

Volumn 24, Issue 1, 2006, Pages 46-50

  Klotz, Laurence ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

Active surveillance; Prostate cancer; Prostate specific antigen doubling time

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

CANCER EPIDEMIOLOGY; CANCER GROWTH; CANCER PALLIATIVE THERAPY; CANCER RISK; CANCER SURVIVAL; CONFERENCE PAPER; DATA BASE; GLEASON SCORE; HUMAN; METASTASIS; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY;

BIOPSY; DISEASE PROGRESSION; HUMANS; MALE; MODELS, THEORETICAL; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; REFERENCE VALUES; RISK FACTORS;

EID: 30744450505     PISSN: 10781439     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.urolonc.2005.07.002     Document Type: Conference Paper

References (35)

1. I.M. Thompson, P.J. Goodman, C.M. Tangen The influence of finasteride on the development of prostate cancer N Engl J Med 349 2003 215 224
2. T.A. Stamey, M. Caldwell, J.E. McNeal The prostate specific antigen era in the United States is over for prostate cancer what happened in the last 20 years J Urol 172 2004 1297 1301
3. S.A. Arredondo, T.M. Downs, D.P. Lubeck Watchful waiting and health related quality of life for patients with localized prostate cancer data from CaPSURE J Urol 172 2004 1830 1834
4. F.H. Schroder Detection of prostate cancer The impact of the European Randomized Study of Screening for Prostate Cancer (ERSPC) Can J Urol 12 Suppl 1 2005 2 6
5. P.C. Albertsen, J.A. Hanley, J. Fine 20-year outcomes following conservative management of clinically localized prostate cancer JAMA 293 2005 2095 2101
6. J.E. Johansson, H.O. Adami, S.O. Andersson High 10 year survival rate in patients with early, untreated prostatic cancer JAMA 267 1992 2191 2196
7. J.E. Johansson, L. Holmberg, S. Johansson Fifteen-year survival in prostate cancer. A prospective, population-based study in Sweden JAMA 277 1997 467 471
8. K.A. Hanash, D.C. Utz, E.N. Cook Carcinoma of the prostate A 15-year followup J Urol 107 1972 450 453
9. G.B. Cook, F.R. Watson Twenty nodules of prostate cancer not treated by total prostatectomy J Urol 100 1968 672 674
10. R. Barnes, A. Hirst, R. Rosenquist Early carcinoma of the prostate Comparison of stages A and B J Urol 115 1976 404 405
11. S.P. Lerner, C. Seale-Hawkins, C.E. Carlton The risk of dying of prostate cancer in patients with clinically localized disease J Urol 146 1991 1040 1045
12. R. Handley, T.W. Carr, D. Travis Deferred treatment for prostate cancer Br J Urol 62 1988 249 253
13. J. Adolfsson, J. Carstensen, T. Lowhagen Deferred treatment in clinically localized prostate carcinoma Brit J Urol 69 1992 183 187
14. G. Waaler, A.E. Stenwig Prognosis of localised prostatic cancer managed by "Watch and Wait" policy Br J Urol 72 1993 214 219
15. W.F. Whitmore, I.A. Warner, I.M. Thompson Expectant management of localized prostatic cancer Cancer 67 1991 1091 1096
16. N.J.R. George Natural history of localised prostatic cancer managed by conservative therapy alone Lancet 1 1988 494 496
17. G. Aus, I. Hugosson, L. Norlen Long-term survival and mortality in prostate cancer treated with noncurative intent J Urol 154 1995 460 465
18. G. Sandblom, M. Dufmats, E. Varenhorst Long-term survival in a Swedish population-based cohort of men with prostate cancer Urology 56 2000 442 447
19. P.O. Madsen, P.H. Graversen, T.C. Gasser Treatment of localized prostatic cancer. Radical prostatectomy versus placebo. A 15-year follow-up Scand J Urol Nephrol Suppl 110 1988 95 100
20. A. Bill-Axelson, L. Holmberg, M. Ruutu Radical prostatectomy versus watchful waiting in early prostate cancer N Engl J Med 352 2005 1977 1984
21. T.A. Stamey, C.M. Yemoto, J.E. McNeal Prostate cancer is highly predictable A prognostic equation based on all morphological variables in radical prostatectomy specimens J Urol 163 2000 1155 1160
22. C.R. Pound, A.W. Partin, M.A. Eisenberger Natural history of progression after PSA elevation following radical prostatectomy JAMA 281 1999 1591 1597
23. A.V. D'Amico, M.H. Chen, K.A. Roehl Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy N Engl J Med 351 2004 125 135
24. J.I. Epstein, P.C. Walsh, M. Carmichael Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer JAMA 271 1994 368 374
25. P.J. Bastian, L.A. Mangold, J.I. Epstein Characteristics of insignificant clinical T1c prostate tumors. A contemporary analysis Cancer 101 2004 2001 2005
26. M.B. Irwin, J.G. Trapasso Identification of insignificant prostate cancers Analysis of preoperative parameters Urology 44 1994 862 867 discussion 867-8.
27. M.R. Cupp, D.G. Bostwick, R.P. Myers The volume of prostate cancer in the biopsy specimen cannot reliably predict the quantity of cancer in the radical prostatectomy specimen on an individual basis J Urol 153 1995 1543 1548
28. Y. Goto, M. Ohori, A. Arakawa Distinguishing clinically important from unimportant prostate cancers before treatment Value of systematic biopsies J Urol 156 1996 1059 1063
29. J.I. Epstein, D.W. Chan, L.J. Sokoll Nonpalpable stage T1c prostate cancer Prediction of insignificant disease using free/total prostate specific antigen levels and needle biopsy findings J Urol 160 1998 2407 2411
30. M. Noguchi, T.A. Stamey, J.E. McNeal Relationship between systematic biopsies and histological features of 222 radical prostatectomy specimens Lack of prediction of tumor significance for men with nonpalpable prostate cancer J Urol 166 2001 104 109
31. H. Augustin, P.G. Hammerer, M. Graefen Insignificant prostate cancer in radical prostatectomy specimen Time trends and preoperative prediction Eur Urol 43 2003 455 460
32. J.W. Anast, G.L. Andriole, T.A. Bismar Relating biopsy and clinical variables to radical prostatectomy findings Can insignificant and advanced prostate cancer be predicted in a screening population Urology 64 2004 544 550
33. L. Klotz Active surveillance with selective delayed intervention Using natural history to guide treatment in good risk prostate cancer J Urol 172 2004 S48 S50
34. R. Choo, G. DeBoer, L. Klotz PSA doubling time of prostate carcinoma managed with watchful observation alone Int J Radiat Oncol Biol Phys 50 2001 615 620
35. R. Choo, L. Klotz, C. Danjoux Feasibility study of watchful waiting for localized low to intermediate grade prostate cancer with selective delayed intervention based on PSA, histologic, and/or clinical progression J Urol 167 2002 1664 1669